Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Chiang

Dermatopathology Spring, TX Medical Doctor

NPI 1568531739 CMS profile 116714

5061 Fm 2920, Spring, TX 77388

Open in the dashboard

General payments

$162,571

352 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$87,823 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Melissa Chiang of Spring, TX is reported in the CMS Open Payments database as having received $162,571 across 352 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $87,823 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Dermatopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,239 37
2024 General $16,501 55
2023 General $11,371 34
2022 General $46,835 81
2021 General $33,525 42
2020 General $20,417 26
2019 General $24,683 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Chiang
  • Dermatopathology median
  • Middle half of Dermatopathology
  • National median

In program year 2025, general payments to Melissa Chiang were reported at $9,239. Among 238 Dermatopathology profiles paid that year, the median was $251 and the middle half received between $93 and $1,140.

Show as a table
Year Melissa Chiang Dermatopathology median Middle half National median
2019 $24,683 $295 $101–$807 $163
2020 $20,417 $154 $53–$443 $114
2021 $33,525 $226 $66–$781 $132
2022 $46,835 $258 $76–$906 $149
2023 $11,371 $303 $93–$1,129 $160
2024 $16,501 $324 $101–$1,343 $164
2025 $9,239 $251 $93–$1,140 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $138,435 178 payments
  2. Merz North America, Inc. $10,270 46 payments
  3. AbbVie, Inc. $8,174 59 payments
  4. Allergan Inc. $4,792 56 payments
  5. Revance Therapeutics, Inc. $469 5 payments
  6. Incyte Corporation $156 1 payment
  7. Davol Inc. $94 1 payment
  8. Celgene Corporation $51 1 payment
  9. LEO Pharma Inc. $46 1 payment
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $42 1 payment
  11. Other $42 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $124,458 36 payments
  2. Consulting Fee $16,556 7 payments
  3. Food and Beverage $11,375 224 payments
  4. Travel and Lodging $10,140 83 payments
  5. Gift $34 1 payment
  6. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Xeomin Dermatology $9,881 41 payments
  2. BOTOX $4,951 62 payments
  3. BOTOX COSMETIC $618 12 payments
  4. ASCLERA $535 3 payments
  5. DAXXIFY $357 4 payments
  6. OPZELURA $156 1 payment
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS $144 5 payments
  8. DYSPORT $135 2 payments
  9. DAXI $112 1 payment
  10. Xeomin musculoskeletal $107 1 payment
  11. Other $392 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatopathology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record